PT2280706E - Composições compreendendo derivados de benzeno que activam lipase de lipoproteína - Google Patents
Composições compreendendo derivados de benzeno que activam lipase de lipoproteínaInfo
- Publication number
- PT2280706E PT2280706E PT87530226T PT08753022T PT2280706E PT 2280706 E PT2280706 E PT 2280706E PT 87530226 T PT87530226 T PT 87530226T PT 08753022 T PT08753022 T PT 08753022T PT 2280706 E PT2280706 E PT 2280706E
- Authority
- PT
- Portugal
- Prior art keywords
- lipoprotein lipase
- benzene derivatives
- activating compositions
- activating
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2008/059294 WO2009139076A1 (en) | 2008-05-14 | 2008-05-14 | Lipoprotein lipase-activating compositions comprising benzene derivates |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2280706E true PT2280706E (pt) | 2013-02-19 |
Family
ID=40289240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT87530226T PT2280706E (pt) | 2008-05-14 | 2008-05-14 | Composições compreendendo derivados de benzeno que activam lipase de lipoproteína |
Country Status (17)
Country | Link |
---|---|
US (2) | US20110065728A1 (pt) |
EP (1) | EP2280706B1 (pt) |
JP (1) | JP5398743B2 (pt) |
KR (1) | KR101492308B1 (pt) |
CN (1) | CN102026637B (pt) |
AU (1) | AU2008356303B2 (pt) |
BR (1) | BRPI0822685A2 (pt) |
CA (1) | CA2723455C (pt) |
DK (1) | DK2280706T3 (pt) |
ES (1) | ES2399689T3 (pt) |
HK (1) | HK1154777A1 (pt) |
MX (1) | MX2010012429A (pt) |
PL (1) | PL2280706T3 (pt) |
PT (1) | PT2280706E (pt) |
TW (1) | TWI409065B (pt) |
WO (1) | WO2009139076A1 (pt) |
ZA (1) | ZA201007319B (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2750704C (en) * | 2009-02-04 | 2016-11-22 | Otsuka Pharmaceutical Factory, Inc. | Phenylimidazole compounds |
GB201302927D0 (en) * | 2013-02-20 | 2013-04-03 | Cancer Therapeutics Crc Pty Ltd | Compounds |
WO2016034673A1 (en) | 2014-09-03 | 2016-03-10 | Ctxt Pty Ltd | Tetrahydroisoquinoline derived prmt5-inhibitors |
GB201415573D0 (en) | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
WO2016034671A1 (en) | 2014-09-03 | 2016-03-10 | Ctxt Pty Ltd | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors |
MX2018003903A (es) * | 2015-09-29 | 2018-09-21 | Oncotherapy Science Inc | Compuesto biciclico y uso del mismo para inhibicion de suv39h2. |
KR102318395B1 (ko) * | 2015-12-25 | 2021-10-27 | 가부시키가이샤 오츠카 세이야쿠 코죠 | 페닐이미다졸 화합물 |
GB201604027D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604031D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604029D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604030D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604022D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604020D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
EP3453706A1 (en) | 2017-09-08 | 2019-03-13 | Basf Se | Pesticidal imidazole compounds |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH483276A (de) | 1959-09-23 | 1969-12-31 | Ciba Geigy | Verwendung von 2-Phenyl-benzazolen als Schutzmittel vor ultravioletter Strahlung ausserhalb der Textilindustrie |
US3669979A (en) | 1967-12-14 | 1972-06-13 | Gaf Corp | Novel process for the production of 2-benzothiazolyl-phenol and derivatives thereof employing phosphorus trichloride as a catalyst |
US3647812A (en) | 1969-04-22 | 1972-03-07 | Richard F Smith | Halogenated 2(2'-hydroxyphenyl benzothiazoles |
US3876791A (en) | 1973-11-30 | 1975-04-08 | Uniroyal Inc | Control of acarids using certain benzothiazoles or benzothiazolines |
PT77844B (en) | 1982-12-27 | 1986-05-08 | Lilly Co Eli | Process for preparing substituted imidazopyrimidines -pyrazines and -triazines |
DE3446778A1 (de) * | 1984-12-21 | 1986-07-03 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue imidazoderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel |
US4714762A (en) * | 1986-10-31 | 1987-12-22 | Warner-Lambert Company | Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof |
US5179117A (en) * | 1991-12-20 | 1993-01-12 | Du Pont Merck Pharmaceutical Company | Antihypercholesterolemic 2-substituted imidazoles |
JP3477238B2 (ja) | 1994-04-27 | 2003-12-10 | 株式会社大塚製薬工場 | イミダゾ〔1,2−a〕ピリジン誘導体 |
JPH07291976A (ja) | 1994-04-27 | 1995-11-07 | Otsuka Pharmaceut Factory Inc | イミダゾ〔2,1−b〕チアゾール誘導体 |
ZA953311B (en) | 1994-04-29 | 1996-10-24 | Lilly Co Eli | Non-peptidyl tachykinin receptor antagonists |
JPH10324688A (ja) | 1997-03-21 | 1998-12-08 | Takeda Chem Ind Ltd | イミダゾピリジン誘導体およびその製造法 |
JP2001226358A (ja) * | 1999-10-12 | 2001-08-21 | Japan Tobacco Inc | Lpl活性増強剤 |
JP2001163861A (ja) | 1999-12-07 | 2001-06-19 | Nippon Soda Co Ltd | ジフェニルイミダゾール化合物および農園芸用殺菌剤 |
US6596731B2 (en) | 2001-03-27 | 2003-07-22 | Hoffmann-La Roche Inc. | Substituted imidazo[1,2-A] pyridine derivatives |
JP2006182668A (ja) * | 2004-12-27 | 2006-07-13 | Dainippon Sumitomo Pharma Co Ltd | 高脂質症、動脈硬化、および/またはメタボリックシンドローム治療剤 |
JP2008540586A (ja) * | 2005-05-18 | 2008-11-20 | フォルシュングスフェアブント ベルリン エー ファウ | Akap−pka相互作用の非ペプチド阻害剤 |
BRPI0707719A2 (pt) * | 2006-02-10 | 2011-05-10 | Summit Corp Plc | uso de um composto ou de um sal farmaceuticamente aceitÁvel do mesmo |
WO2008029152A2 (en) * | 2006-09-08 | 2008-03-13 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
EP1964840A1 (en) * | 2007-02-28 | 2008-09-03 | sanofi-aventis | Imidazo[1,2-a]pyridines and their use as pharmaceuticals |
CA2750704C (en) * | 2009-02-04 | 2016-11-22 | Otsuka Pharmaceutical Factory, Inc. | Phenylimidazole compounds |
-
2008
- 2008-05-14 JP JP2010545320A patent/JP5398743B2/ja active Active
- 2008-05-14 MX MX2010012429A patent/MX2010012429A/es active IP Right Grant
- 2008-05-14 DK DK08753022.6T patent/DK2280706T3/da active
- 2008-05-14 AU AU2008356303A patent/AU2008356303B2/en not_active Ceased
- 2008-05-14 PT PT87530226T patent/PT2280706E/pt unknown
- 2008-05-14 PL PL08753022T patent/PL2280706T3/pl unknown
- 2008-05-14 KR KR1020107026147A patent/KR101492308B1/ko not_active IP Right Cessation
- 2008-05-14 WO PCT/JP2008/059294 patent/WO2009139076A1/en active Application Filing
- 2008-05-14 US US12/992,394 patent/US20110065728A1/en not_active Abandoned
- 2008-05-14 ES ES08753022T patent/ES2399689T3/es active Active
- 2008-05-14 BR BRPI0822685-7A patent/BRPI0822685A2/pt active Search and Examination
- 2008-05-14 EP EP08753022A patent/EP2280706B1/en not_active Not-in-force
- 2008-05-14 CN CN2008801291789A patent/CN102026637B/zh not_active Expired - Fee Related
- 2008-05-14 CA CA2723455A patent/CA2723455C/en not_active Expired - Fee Related
- 2008-05-15 TW TW097117840A patent/TWI409065B/zh not_active IP Right Cessation
-
2010
- 2010-10-13 ZA ZA2010/07319A patent/ZA201007319B/en unknown
-
2011
- 2011-06-21 HK HK11106357.1A patent/HK1154777A1/xx not_active IP Right Cessation
-
2013
- 2013-06-28 US US13/931,196 patent/US8895599B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
PL2280706T3 (pl) | 2013-05-31 |
EP2280706A1 (en) | 2011-02-09 |
WO2009139076A1 (en) | 2009-11-19 |
MX2010012429A (es) | 2010-12-21 |
JP2011520775A (ja) | 2011-07-21 |
TWI409065B (zh) | 2013-09-21 |
US8895599B2 (en) | 2014-11-25 |
HK1154777A1 (en) | 2012-05-04 |
ZA201007319B (en) | 2012-01-25 |
US20110065728A1 (en) | 2011-03-17 |
AU2008356303A1 (en) | 2009-11-19 |
DK2280706T3 (da) | 2013-02-04 |
US20130296342A1 (en) | 2013-11-07 |
KR101492308B1 (ko) | 2015-02-11 |
KR20110005886A (ko) | 2011-01-19 |
CN102026637B (zh) | 2012-12-12 |
JP5398743B2 (ja) | 2014-01-29 |
ES2399689T3 (es) | 2013-04-02 |
EP2280706B1 (en) | 2013-01-02 |
CA2723455C (en) | 2015-04-28 |
BRPI0822685A2 (pt) | 2015-06-30 |
CA2723455A1 (en) | 2009-11-19 |
TW200946116A (en) | 2009-11-16 |
CN102026637A (zh) | 2011-04-20 |
AU2008356303B2 (en) | 2013-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1154777A1 (en) | Lipoprotein lipase-activating compositions comprising benzene derivatives | |
MX2009000884A (es) | Derivados de piridizinona. | |
MX2011011661A (es) | Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750. | |
TW200801003A (en) | Novel compounds | |
MX2010009022A (es) | Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso. | |
TW200726753A (en) | 2,4-diamino-pyrimidines as aurora inhibitors | |
MY153915A (en) | Organic compounds | |
IN2012DN01233A (pt) | ||
MX2010009752A (es) | Compuestos de oxadiazoantraceno para el tratamiento de diabetes. | |
JO3408B1 (ar) | مركبات بترين سلفون اميد ثيازول و أوكسازول | |
RS20090249A (en) | Spiroketone acetyl-coa carboxylase inhibotors | |
TW200745114A (en) | Novel compounds | |
TW200745122A (en) | New compounds I | |
MX2009005462A (es) | Analogos de 7,8-saturados-4,5-epoxi-morfinano. | |
TW200738659A (en) | Novel compounds | |
TW200745084A (en) | Novel compounds | |
TW200612936A (en) | Indole derivatives | |
DE602006006712D1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
MY148948A (en) | Catecholamine derivatives and prodrugs thereof | |
JO2578B1 (en) | Compounds Theophene benzimidazole | |
MX2010005649A (es) | Compuestos novedosos como ligandos del receptor canabinoide y sus usos. | |
TW200740781A (en) | Novel compounds | |
TW200639156A (en) | New compounds | |
GEP20135959B (en) | Aryl piperazine and their usage as alpha2c antagonists | |
MX2009006010A (es) | Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2. |